All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.